These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 37686060)

  • 1. Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
    Cincotta AH
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
    Ezrokhi M; Zhang Y; Luo S; Cincotta AH
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
    Raskin P; Cincotta AH
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):113-148. PubMed ID: 30058874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
    Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
    J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
    Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
    Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
    Cincotta AH; Cersosimo E; Alatrach M; Ezrokhi M; Agyin C; Adams J; Chilton R; Triplitt C; Chamarthi B; Cominos N; DeFronzo RA
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet.
    Luo S; Zhang Y; Ezrokhi M; Li Y; Tsai TH; Cincotta AH
    J Neuroendocrinol; 2018 Jan; 30(1):. PubMed ID: 29224246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
    Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
    J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster.
    Luo S; Luo J; Cincotta AH
    Chronobiol Int; 2000 Mar; 17(2):155-72. PubMed ID: 10757461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
    Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
    Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
    Gaziano JM; Cincotta AH; O'Connor CM; Ezrokhi M; Rutty D; Ma ZJ; Scranton RE
    Diabetes Care; 2010 Jul; 33(7):1503-8. PubMed ID: 20332352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.
    Ezrokhi M; Luo S; Trubitsyna Y; Cincotta AH
    Diabetol Metab Syndr; 2014; 6():104. PubMed ID: 25937836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats.
    Nade VS; Kawale LA; Todmal UB; Tajanpure AB
    Indian J Pharmacol; 2012; 44(6):688-93. PubMed ID: 23248395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor.
    Framnes-DeBoer SN; Bakke E; Yalamanchili S; Peterson H; Sandoval DA; Seeley RJ; Arble DM
    Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E62-E71. PubMed ID: 31794265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D
    Wei H; Zapata RC; Lopez-Valencia M; Aslanoglou D; Farino ZJ; Benner V; Osborn O; Freyberg Z; McCarthy MJ
    Psychoneuroendocrinology; 2020 Mar; 113():104551. PubMed ID: 31884319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
    Siamashvili M; Davis S
    Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.
    Chamarthi B; Vinik A; Ezrokhi M; Cincotta AH
    Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00101. PubMed ID: 31922028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.